United States Federal Circuit

ResetAA Font size: Print

Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc., 17-1487

Reversing the US Patent and Trademark Office's Patent Trial and Appeal Board decision regarding the As Sawaya Declarations, vacating the determination that test data did not satisfy statutory requirements and that the Asserted Claims would not have been obvious and remanding for further consideration in a case relating to pupil dilation drugs.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2018/05/11




  • United States Federal Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  Careers Home

    View More